Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more
Harbin Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Harbin Pharmaceutical Group Co Ltd (600664) has an Asset Resilience Ratio of 0.97% as of September 2012. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2006)
This chart shows how Harbin Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Harbin Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥150.00 Million | 0.97% |
| Total Liquid Assets | CN¥150.00 Million | 0.97% |
Asset Resilience Insights
- Limited Liquidity: Harbin Pharmaceutical Group Co Ltd maintains only 0.97% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Harbin Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Harbin Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Cronos Group Inc
NASDAQ:CRON |
Drug Manufacturers - Specialty & Generic | 3.34% |
|
Evoke Pharma Inc
NASDAQ:EVOK |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Medical Marijuana I
PINK:MJNA |
Drug Manufacturers - Specialty & Generic | 0.03% |
|
James E Wagner Cultivation Corp
PINK:JWCAF |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
CanaQuest Medical Corp
PINK:CANQF |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Innovativ Media Group Inc
PINK:DMAN |
Drug Manufacturers - Specialty & Generic | 53.58% |
Annual Asset Resilience Ratio for Harbin Pharmaceutical Group Co Ltd (1993–2006)
The table below shows the annual Asset Resilience Ratio data for Harbin Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2006-12-31 | 0.02% | CN¥2.00 Million | CN¥9.40 Billion | +0.02pp |
| 2003-12-31 | 0.00% | CN¥52.00K | CN¥6.58 Billion | 0.00pp |
| 2002-12-31 | 0.00% | CN¥59.00K | CN¥5.95 Billion | 0.00pp |
| 2001-12-31 | 0.00% | CN¥224.00K | CN¥5.77 Billion | -0.01pp |
| 2000-12-31 | 0.01% | CN¥436.00K | CN¥4.45 Billion | -0.01pp |
| 1997-12-31 | 0.02% | CN¥462.10K | CN¥2.90 Billion | -0.01pp |
| 1996-12-31 | 0.02% | CN¥582.32K | CN¥2.49 Billion | -0.05pp |
| 1995-12-31 | 0.07% | CN¥1.79 Million | CN¥2.40 Billion | -0.16pp |
| 1994-12-31 | 0.24% | CN¥5.60 Million | CN¥2.35 Billion | -0.04pp |
| 1993-12-31 | 0.28% | CN¥6.30 Million | CN¥2.24 Billion | -- |